- Avstrija / Österreich
- Bosna in Hercegovina / Босна и Херцеговина
- Bolgarija / България
- Hrvaška / Hrvatska
- Češka & Slovaška / Česká republika & Slovensko
- Francija / France
- Nemčija / Deutschland
- Grčija / ΕΛΛΑΔΑ
- Italija / Italia
- Nizozemska / Nederland
- Nordijska / Nordic
- Poljska / Polska
- Portugalska / Portugal
- Romunija & Moldavija / România & Moldova
- Slovenija / Slovenija
- Srbija & Črna gora / Србија и Црна Гора
- Španija / España
- Švica / Schweiz
- Turčija / Türkiye
- Velika Britanija in Irska / UK & Ireland
Terapija botoksa lahko v veliki meri pomaga, z le blagim tveganjem negativnih učinkov na bolnike z bolečinami v mišicah, ki so prisotne pri žvečenju, v skladu z novo retrospektivno študijo. Kemično znan kot botulinum toksin A, je botoks beljakovina, ki je izdelana iz bakterij, ki ob injiciranju prekine prenos živčnih signalov, s katerimi se mišice krčijo, kar pomeni, da se mišična aktivnost zmanjša za več mesecev. Botoks so uporabili za zdravljenje bolezni, kot so mišični krči, obrazne gube, migrene in prekomerno znojenje.
According to the study published in the November issue of the Journal of Oral and Maxillofacial Surgery — the official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS) — botulinum toxin A injections also may have pain-relieving properties.
To determine the therapy’s safety and effectiveness in treating stubborn jaw muscle pain, researchers conducted a retrospective review of 116 patients. The patients underwent at least two Botox injection cycles for refractory masticatory myalgia —pain in the muscles used for chewing — that had not responded to other therapies.
The patients at the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital also had coexisting chronic pain disorders and were receiving other therapies and/or taking medications.
Nearly one-third of participants (30.6 percent) reported significant pain relief — defined as 75 percent or greater — for an average of 10.1 weeks.
“This is an important outcome for this particular cohort of participants, considering that 72.9 percent of the participants had been in pain for at least five years, with 60 percent or more receiving two or more concurrent therapies,” researchers wrote.
In addition, 39.8 percent of participants had moderate relief for 8.7 weeks on average, and 29.6 percent had no or minimal relief for 1.3 weeks on average.
Among the participants, 16.4 percent reported at least one negative effect during the two injection cycles. Those who had significant pain relief had the largest number of adverse effects at 30.3 percent.
The most common side effect was a decrease in the size of the masticatory muscle, possibly due to blocked release of a chemical that activates muscles, the study states. However, all of the negative effects were minor and brief, and full recovery occurred within 16 weeks.
Simultaneous use of opioid pain relievers was a predictor of no or minimal relief. Of the participants, 36 percent were using a long-term opioid therapy. Long-term opioid use can result in opioid-induced hyperalgesia — a painful response to the medications — and having chronic pain disorders can lead to diminished effect of pain relievers, researchers wrote. “Together, these factors may result in poor outcome and response to therapy,” they said.
The authors of “Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study” are all from the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital: David A. Keith, DMD, BDS, professor at Harvard School of Dental Medicine; Steven J. Scrivani, DDS, DMedSc, chief, Division of Oral and Maxillofacial Pain; Nicole Holland, DDS, MS; and Shehryar N. Khawaja, BDS, MS, post-graduate Fellow at Harvard School of Dental Medicine.
The full article can be accessed at www.joms.org/article/S0278-2391(17)30116-7/fulltext.
About JOMS
The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dentoalveolar surgery, facial injuries and deformities, TMJ disorders, oral and head and neck cancer, jaw reconstruction, anesthesia and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.
(Source: Journal of Oral and Maxillofacial Surgery)
pon. 29 april 2024
6:30 (CET) Ljubljana
Root caries: The challenge in today’s cariology
tor. 30 april 2024
7:00 (CET) Ljubljana
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
pet. 3 maj 2024
7:00 (CET) Ljubljana
Osseointegration in extrēmus: Complex maxillofacial reconstruction & rehabilitation praeteritum, praesens et futurum
sre. 8 maj 2024
2:00 (CET) Ljubljana
You got this! Diagnosis and management of common oral lesions
pet. 10 maj 2024
2:00 (CET) Ljubljana
Empowering your restorative practice: A comprehensive guide to clear aligner integration and success
pon. 13 maj 2024
3:00 (CET) Ljubljana
CREATING MORE PRACTICE TIME THROUGH EFFICIENCY: IMPROVED ACCURACY AND DELEGATION
pon. 13 maj 2024
7:00 (CET) Ljubljana
To post a reply please login or register